Holen Sie sich die Stockscreener-App
83.80
0.64%
-0.518
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$84.32
Offen:
$84.59
24-Stunden-Volumen:
1.07M
Relative Volume:
0.24
Marktkapitalisierung:
$48.59B
Einnahmen:
$5.88B
Nettoeinkommen (Verlust:
$1.34B
KGV:
35.68
EPS:
2.3489
Netto-Cashflow:
$799.60M
1W Leistung:
-1.10%
1M Leistung:
+0.47%
6M Leistung:
+9.72%
1J Leistung:
+18.17%
1-Tages-Spanne:
$83.53
$85.19
1-Wochen-Bereich:
$83.53
$87.89
52-Wochen-Spanne:
$65.94
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Vergleichen Sie EW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
83.74 | 48.93B | 5.88B | 1.34B | 799.60M | 2.3489 |
|
ABT
Abbott Laboratories
|
121.60 | 212.30B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.96 | 139.11B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
351.14 | 135.23B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.47 | 129.82B | 34.76B | 4.79B | 5.21B | 3.7017 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Hochstufung | Jefferies | Hold → Buy |
| 2025-10-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-04-24 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Vega Investment Solutions Has $28,000 Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation $EW Shares Purchased by Natixis - MarketBeat
Edwards Lifesciences Corporation $EW Stock Position Increased by 2Xideas AG - MarketBeat
Edwards Lifesciences’ Markowitz sells $50k in stock By Investing.com - Investing.com UK
Edwards Lifesciences’ Markowitz sells $50k in stock - Investing.com
Barclays Raises Edwards Lifesciences (EW) Price Target to $103.0 - GuruFocus
Leerink Partners Adjusts Edwards Lifesciences PT to $87 From $88, Maintains Market Perform Rating - marketscreener.com
WINTON GROUP Ltd Acquires 43,197 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences stock price target raised to $95 from $90 at Bernstein - Investing.com
Invesco Ltd. Decreases Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (NYSE:EW) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Raised to $100.00 at Royal Bank Of Canada - MarketBeat
Edwards Lifesciences (NYSE:EW) Stock Price Expected to Rise, Robert W. Baird Analyst Says - MarketBeat
Epoch Investment Partners Inc. Has $20.45 Million Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (EW): Stifel Raises Price Target to $100 | - GuruFocus
Edwards Lifesciences (EW) Sees Analyst Target Price Increase Tod - GuruFocus
Amundi Raises Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
UBS Maintains Neutral Rating on Edwards Lifesciences (EW) and Ra - GuruFocus
Edwards Lifesciences (EW) Analyst Rating Update for December 5, 2025 | EW Stock News - GuruFocus
Edwards Lifesciences (EW): Reassessing Valuation After Upbeat 2025–2026 Outlook and TAVR Growth Signals - Yahoo Finance
Edwards Lifesciences Sets Cautious Targets Yet Keeps Investors Interested - Finimize
Edwards Lifesciences : EW 2025 IC FINAL - marketscreener.com
Bernstein Adjusts Edwards Lifesciences Price Target to $95 From $90, Maintains Market Perform Rating - marketscreener.com
Wells Fargo Adjusts Price Target for Edwards Lifesciences (EW) | - GuruFocus
Edwards Lifesciences' Long-term Business Outlook Appears Achievable, RBC Says - marketscreener.com
Edwards Lifesciences Bags Prosthetic Valve Patent In EU - Law360
Truist Securities Raises Price Target for Edwards Lifesciences (EW) | EW Stock News - GuruFocus
How Do Investors Really Feel About Edwards Lifesciences Corp? - Benzinga
Edwards Lifesciences stock hits 52-week high at 87.42 USD By Investing.com - Investing.com Nigeria
Edwards Lifesciences stock hits 52-week high at 87.42 USD - Investing.com
Raymond James Adjusts PT on Edwards Lifesciences to $100 From $96, Maintains Outperform Rating - marketscreener.com
UBS Adjusts Price Target on Edwards Lifesciences to $92 From $90, Maintains Neutral Rating - marketscreener.com
Edwards Lifesciences price target raised to $92 from $90 at UBS - Investing.com
RBC Capital raises Edwards Lifesciences stock price target to $100 on 2026 outlook - Investing.com
Truist Securities Adjusts PT on Edwards Lifesciences to $92 From $90, Maintains Hold Rating - marketscreener.com
Edwards Lifesciences price target raised to $100 from $95 at Stifel - TipRanks
RBC Raises Price Target on Edwards Lifesciences to $100 From $95, Keeps Outperform Rating - marketscreener.com
Stifel Adjusts Price Target on Edwards Lifesciences to $100 From $95, Maintains Buy Rating - marketscreener.com
Wells Fargo Adjusts Price Target on Edwards Lifesciences to $96 From $95, Maintains Overweight Rating - marketscreener.com
Barclays Adjusts Price Target on Edwards Lifesciences to $103 From $99, Maintains Overweight Rating - marketscreener.com
Canaccord Genuity Adjusts Price Target on Edwards Lifesciences to $89 From $84, Maintains Hold Rating - marketscreener.com
Edwards Lifesciences price target raised to $89 from $84 at Canaccord - TipRanks
Edwards Lifesciences stock price target raised to $92 from $90 at Truist - Investing.com Nigeria
Analyst BTIG Raises Price Target for Edwards Lifesciences (EW) t - GuruFocus
Edwards Lifesciences stock price target raised to $100 by Stifel - Investing.com South Africa
Edwards Lifesciences price target raised to $96 from $95 at Wells Fargo - TipRanks
Does Edwards Lifesciences’ Analyst Day Transcatheter Pipeline Update Reframe the Bull Case for EW? - simplywall.st
Edwards Lifesciences stock price target raised to $89 from $84 at Canaccord - Investing.com
Edwards Lifesciences stock price target raised to $103 from $100 at BTIG - Investing.com
Edwards Lifesciences Corporation $EW Shares Sold by Brown Advisory Inc. - MarketBeat
Edwards Lifesciences: Strategic Initiatives and Promising Developments Drive Raised Price Target - TipRanks
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.33%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):